AML Mutation Profiles and MRD Data for Clinical Prognostication in Hong Kong

A dataset by Sze Pui Tsui, last updated April 2026, supporting research on acute myeloid leukemia (AML). It likely contains clinicodemographic features, mutational data at diagnosis, and treatment outcomes for cytogenetically normal and Trisomy AML cohorts in Hong Kong. The dataset also includes selected MRD markers and post-HSCT results for monitoring minimal residual disease.

Use Cases

• Characterize mutation landscapes of CN-AML and Trisomy AML based on next-generation sequencing data.
• Compare treatment responses and survival outcomes with overseas results using clinicodemographic and outcome data.
• Investigate impacts of mutations on leukemia remission and overall survival for improved prognostication.
• Establish a sensitive platform for MRD detection and monitoring post-HSCT based on droplet-digital PCR results.
• Guide decisions on allo-HSCT at CR1 using integrated mutational and clinical outcome data.

Strengths

• Focuses on two specific and large cytogenetic groups in AML (CN-AML and Trisomy AML) as described.
• Integrates diagnostic mutational data with treatment outcomes and post-HSCT MRD monitoring data.
• Data is associated with a specific geographic cohort (Hong Kong) and a defined patient population (young and fit receiving conventional chemotherapy and allo-HSCT).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

figshare

Collection Method

Data likely gathered from clinical studies using next-generation sequencing and droplet-digital PCR.

Freshness

Last updated 2026-04-29 05:19:35; freshness should be verified.

Geography

Hong Kong